Comparative Pharmacology
Head-to-head clinical analysis: BETAXON versus NADOLOL AND BENDROFLUMETHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAXON versus NADOLOL AND BENDROFLUMETHIAZIDE.
BETAXON vs NADOLOL AND BENDROFLUMETHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production through inhibition of beta-1 receptors in the ciliary epithelium.
Nadolol is a nonselective beta-adrenergic receptor antagonist that blocks beta1 and beta2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Bendroflumethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water and reducing plasma volume.
0.25% ophthalmic solution, 1 drop in the affected eye(s) twice daily.
Nadolol 40–80 mg orally once daily; bendroflumethiazide 2.5–5 mg orally once daily. Dose titration based on blood pressure response.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 36 hours).
Nadolol: 14–24 h (mean 20 h); allows once-daily dosing. Bendroflumethiazide: 3–4 h (terminal); clinical duration longer due to prolonged action on distal tubule.
Primarily renal (40-50% unchanged) and fecal (30-40% as metabolites); biliary excretion contributes minimally.
Nadolol: ~70% renal unchanged, ≤5% fecal. Bendroflumethiazide: ~30% renal unchanged, ~70% renal as metabolites; minimal biliary.
Category C
Category C
Beta-Blocker
Beta-Blocker